Predicting Adverse Drug Events Using Pharmacological Network Models

被引:101
作者
Cami, Aurel [1 ,2 ]
Arnold, Alana [1 ]
Manzi, Shannon [1 ]
Reis, Ben [1 ,2 ]
机构
[1] Childrens Hosp Boston, Boston, MA 02115 USA
[2] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA
关键词
IN-SILICO; DISCOVERY TOXICOLOGY; SAFETY; TOXICITY; PHARMACOVIGILANCE; SIMILARITY;
D O I
10.1126/scitranslmed.3002774
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Early and accurate identification of adverse drug events (ADEs) is critically important for public health. We have developed a novel approach for predicting ADEs, called predictive pharmacosafety networks (PPNs). PPNs integrate the network structure formed by known drug-ADE relationships with information on specific drugs and adverse events to predict likely unknown ADEs. Rather than waiting for sufficient post-market evidence to accumulate for a given ADE, this predictive approach relies on leveraging existing, contextual drug safety information, thereby having the potential to identify certain ADEs earlier. We constructed a network representation of drug-ADE associations for 809 drugs and 852 ADEs on the basis of a snapshot of a widely used drug safety database from 2005 and supplemented these data with additional pharmacological information. We trained a logistic regression model to predict unknown drug-ADE associations that were not listed in the 2005 snapshot. We evaluated the model's performance by comparing these predictions with the new drug-ADE associations that appeared in a 2010 snapshot of the same drug safety database. The proposed model achieved an AUROC (area under the receiver operating characteristic curve) statistic of 0.87, with a sensitivity of 0.42 given a specificity of 0.95. These findings suggest that predictive network methods can be useful for predicting unknown ADEs.
引用
收藏
页数:10
相关论文
共 39 条
[1]   Comparative performance of two quantitative safety signalling methods - Implications for use in a pharmacovigilance department [J].
Almenoff, June S. ;
LaCroix, Karol K. ;
Yuen, Nancy A. ;
Fram, David ;
DuMouchel, William .
DRUG SAFETY, 2006, 29 (10) :875-887
[2]  
Atias N, 2010, LECT N BIOINFORMAT, V6044, P1, DOI 10.1007/978-3-642-12683-3_1
[3]  
Berger S, 2011, SYST BIOL MED, V3, P129
[4]   Network analyses in systems pharmacology [J].
Berger, Seth I. ;
Iyengar, Ravi .
BIOINFORMATICS, 2009, 25 (19) :2466-2472
[5]   Monitoring the safety of licensed medicines [J].
Breckenridge, A ;
Woods, K ;
Raine, J .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (07) :1-3
[6]   Early detection of adverse drug events within population-based health networks: application of sequential testing methods [J].
Brown, Jeffrey S. ;
Kulldorff, Martin ;
Chan, K. Arnold ;
Davis, Robert L. ;
Graham, David ;
Pettus, Parker T. ;
Andrade, Susan E. ;
Raebel, Marsha A. ;
Herrinton, Lisa ;
Roblin, Douglas ;
Boudreau, Denise ;
Smith, David ;
Gurwitz, Jerry H. ;
Gunter, Margaret J. ;
Platt, Richard .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (12) :1275-1284
[7]   Can cell systems biology rescue drug discovery? [J].
Butcher, EC .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (06) :461-467
[8]   Predicting ADME properties in silico:: methods and models [J].
Butina, D ;
Segall, MD ;
Frankcombe, K .
DRUG DISCOVERY TODAY, 2002, 7 (11) :S83-S88
[9]   Drug target identification using side-effect similarity [J].
Campillos, Monica ;
Kuhn, Michael ;
Gavin, Anne-Claude ;
Jensen, Lars Juhl ;
Bork, Peer .
SCIENCE, 2008, 321 (5886) :263-266
[10]   Data-Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events [J].
Chiang, A. P. ;
Butte, A. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (03) :259-268